Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02683408 · ClinicalTrials.gov registry record · NA
Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon
A NA study, sponsored by Primus Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 87
- Enrollment target
NCT02683408 is a NA study that has completed, run by Primus Pharmaceuticals. The registered enrollment target is 87 participants.
The verdict
NCT02683408, a NA study, has completed, sponsored by Primus Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 87 participants
- Enrollment target
Study Summary
Diosmiplex is a product marketed for the management of diseases due to venous and microvascular dysfunction. Raynaud's phenomenon is a disorder of characterized by spasm of small arteries and impaired microvascular flow. This study will examine the effects of diosmiplex on the frequency and severity of Raynaud's episodes in susceptible people.
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT diosmiplex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02683408
The ClinicalTrials.gov registry entry for NCT02683408 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Primus Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02683408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02683408 about?
NCT02683408 is a clinical study titled "Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon". Diosmiplex is a product marketed for the management of diseases due to venous and microvascular dysfunction. Raynaud's phenomenon is a disorder of characterized by spasm of small arteries and impaired microvascular flow. This study will examine the effects of diosmiplex on the frequency and severity...
What is the current status of trial NCT02683408?
This trial is currently completed. It is a NA study. The enrollment target is 87 participants. The study started on 2016-02. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02683408?
The interventions under investigation include: placebo (OTHER), diosmiplex (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02683408?
This trial is sponsored by Primus Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.